Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR174 | Q9BXC1 | 8/20 | 0.52 |
| ▸ | SMARCA2 | P51531 | 1/20 | 0.44 |
| ▸ | SMARCA4 | P51532 | 1/20 | 0.44 |
| ▸ | PBRM1 | Q86U86 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 7/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | GPR119 | Q8TDV5 | 4/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.41 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.41 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31397398 | 1.00 | GPR174 (0.52) | GPR174SMARCA2SMARCA4PBRM1MAPT | |
| SCHEMBL31342504 | 0.89 | GPR174 (0.53) | GPR174SMARCA2SMARCA4PBRM1MAPT | |
| SCHEMBL35212186 | 0.89 | GPR174 (0.53) | GPR174SMARCA2SMARCA4PBRM1MAPT | |
| SCHEMBL31397131 | 0.89 | GPR174 (0.53) | GPR174SMARCA2SMARCA4PBRM1MAPT | |
| SCHEMBL22716822 | 0.86 | MAPT (0.57) | GPR174MAPTALDH1A1SMN1; SMN2MEN1 | |
| SCHEMBL30258598 | 0.86 | MAPT (0.57) | GPR174MAPTALDH1A1SMN1; SMN2MEN1 | |
| SCHEMBL24821048 | 0.84 | SMARCA2 (0.53) | GPR174SMARCA2SMARCA4PBRM1GPR119 | |
| SCHEMBL31397468 | 0.84 | SMARCA2 (0.53) | GPR174SMARCA2SMARCA4PBRM1GPR119 | |
| SCHEMBL31397033 | 0.82 | SMARCA2 (0.43) | GPR174SMARCA2SMARCA4PBRM1MAPT | |
| SCHEMBL24480836 | 0.82 | GPR174 (0.50) | GPR174MAPTALDH1A1SMN1; SMN2GPR119 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240424111-A1 | Degrader Compounds and Uses Thereof | CALICO LIFE SCIENCES LLC (US) | 2024-12-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240424111-A1 | Degrader Compounds and Uses Thereof | PTPN1, PTPN2, PTPN5 | GPR174 1934/4885SMARCA2 2238/4885SMARCA4 2953/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.